Please assess the completion status of the following clinical trial:

Trial Title: Study of Sleep-maintenance Activity of 3 Doses of SKP-1041

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Primary insomnia characterized by chronic difficulty maintaining sleep~Exclusion Criteria:~* History of restless legs syndrome, sleep apnea, narcolepsy, or parasomnias;~* Any clinically relevant acute or chronic diseases which could interfere with the patient's safety during this trial or with this tablet's absorption;~* Pregnancy;~* History of medication allergies;~* Use of medication that might interfere with this study;~* Recent travel across more than 3 time zones.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
- 10 mg SKP-1041 (Type: EXPERIMENTAL): One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
- 15 mg SKP-1041 (Type: EXPERIMENTAL): One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
- 20 mg SKP-1041 (Type: EXPERIMENTAL): Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence

Based on this trial design, predict the completion outcome and termination type (if applicable).